Skip Navigation

DRUG RECORD

 

DAPSONE

OVERVIEW
Dapsone

 

Introduction

Dapsone is a sulfonamide related drug used for the therapy of leprosy and dermatitis herpetiformis.  Dapsone has been linked with rare cases of idiosyncratic liver injury, similar to that seen with the sulfonamides.

 

Background

Dapsone (dap' sone) is 4,4’ diaminodiphenylsulfone and is bacteriostatic for Mycobacterium leprae.  Like other sulfonamides, dapsone is believed to act by inhibition of folate synthesis.  Bacteria including M. leprae are acutely sensitive to this inhibition as folate is necessary for protein, DNA and RNA synthesis.  In contast, humans are not affected by this inhibition of folate synthesis because they rely upon dietary sources of folate.  Dapsone was approved for use in the United States in 1979.  Current indications include leprosy and dermatitis herpetiformis.  Off-label uses include prophylaxis against pneumocystis jiroveci (formerly carinii) in HIV infected patients.  Dapsone is available in multiple generic forms in tablets of 25 and 100 mg.  Dapsone is usually started at a low dose in the range of 50 mg daily and titrated upward to a total daily dose of 100 to 300 mg.  In the therapy of leprosy, dapsone is recommended for at least 3 years and may be necessary life long.  Dapsone is also available as a topical gel for therapy of acne.  Common side effects of oral dapsone include hemolysis and anemia, nausea, abdominal pain, tinnitus, vertigo, blurred vision, headache, insomnia, and rash.  Dapsone is not uncommonly associated more severe side effects including peripheral neuropathy, acute psychosis, nephrotic syndrome, acute liver injury, hemolysis, agranulocytosis, aplastic anemia, hypersensitivity reactions and a lupus-like syndrome.

 

Hepatotoxicity

Dapsone, like other sulfonamides, causes a characteristic idiosyncratic liver injury that has features of drug-allergy or hypersensitivity.  The typical onset is sudden development of fever and rash followed by jaundice within a few days or weeks of starting the medication.  Eosinophilia or lymphocytosis are also common.  The pattern of injury is typically cholestatic or mixed and can be complicated and prolonged.  In rare instances, dapsone induced liver injury has resulted in acute liver failure.  However, most cases resolve rapidly, usually within 2 to 4 weeks of stopping dapsone, unless cholestasis is severe.  Hepatic injury can also occur with an infectious mononucleosis-like syndrome or with the “sulfone syndrome” that typically occurs within 6 weeks of starting therapy in malnourished patients marked by rash, fever, systemic symptoms and jaundice and which is a variant of the DRESS syndrome (drug rash with eosinophilia and systemic symptoms).

 

Mechanism of Injury

The clinical pattern of injury with dapsone suggests a drug-allergy or hypersensitivity mechanism, perhaps through its metabolism to a toxic, reactive or antigenic metabolite.

 

Outcome and Management

Dapsone induced liver injury can result in acute liver failure, but most cases resolve rapidly with discontinuation of drug and full recovery is expected within 2 to 8 weeks.  Severe cholestatic injury may be prolonged.  Rechallenge should not be done, and patients should be told that they are allergic to sulfonamides (“sulfa-drugs”) and not receive other drugs in this class.  If dapsone is considered crucial for management, attempts at desensitization can be made.  Prednisone has been used to treat dapsone related liver injury with variable success, but may be particularly helpful in patients with prominent allergic features with systemic features and fever, rash, and eosinophilia.

 

References to the safety and potential hepatotoxicity of dapsone are given in the Overview on Sulfonamides.

 

Drug Class:  Antiinfective Agents, Sulfonamides; Leprosy Agents

 

Top of page

 

PRODUCT INFORMATION
Dapsone


REPRESENTATIVE TRADE NAMES
Dapsone – Generic


DRUG CLASS
Antiinfective Agents


COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

 

Top of page

 

DRUG CAS REGISTRY NO MOLECULAR FORMULA STRUCTURE
Dapsone 80-08-0 C12-H12-N2-O2-S Dapsone  chemical structure

Top of page

 

OTHER REFERENCE LINKS
Dapsone
  1. PubMed logoRecent References on Dapsone

  2. Clinical Trials logoTrials on Dapsone

Top of page